India Today on MSN

99.5 percentile in JEE Main, AIR 2 in NEET 2026: Meet Pranshul, the new academic star

Faridabad student Panshul Bansal secured AIR 2 in NEET UG 2026 after scoring 715 out of 720. His result came after a 99.5 ...
Le Lézard

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Txtm Test

Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health ...

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State ...
admin.ch

10 new professors appointed at ETH Zurich and EPFL

At its meeting of 15/16 July 2026 and upon application of the President of ETH Zurich, Professor Joël Mesot, and the President of EPFL, Professor Anna Fontcuberta i Morral, the ETH Board appointed a ...
TMCnet

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today ...
TMCnet

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation ...
The Manila Times

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an ...

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting ...

Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Dis…

Eisai Limited ("Eisai") and Biogen Canada Inc. are honoured to be one of the first countries in the world to receive a ...

Eisai Inc.: LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's ...

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and ...

Biogen Inc.: FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...